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Abstract
Background: Percutaneous  transcatheter  closure  of
patent foramen ovale (PFo) in cryptogenic stroke is
an alternative to medical therapy. there is still debate
on different outcome for each currently available de-
vice. the impact of residual shunting after PFo-clo-
sure on recurrent arterial embolism is unknown. 
aims: (i) to evaluate the prevalence of residual intera-
trial shunting after device- closure of PFo, (ii) to iden-
tify risk factors predicting residual interatrial shunting
after device implantation, and (iii) to investigate the
outcome of patients after PFo-closure during long-
term follow- up (Fu).
Methods and results: Between 2000- 2005 PFo-closure
was performed in 124 patients using four different de-
vices: amplatzer PFo-(n = 52), cardioseal (n = 33),
Helex (n = 23) and Premere (n = 16) occluder. all pa-
tients  underwent  serial  contrast-enhanced  trans-
esophageal echocardiography (tEE) for 24 months af-
ter PFo- closure; clinical Fu was at minimum 5 years
up to 9.75 years (mean 6.67 ﾱ 1.31 years). overall-clo-
sure rate was 87% at 2 years, device-specific closure
time curves differed significantly (p-logrank = 0.003).
Independent  risk  factors  for  residual-shunting  were
implantation of a Helex occluder (hazard ratio [HR]
12.6,  95%  confidence  interval  [cI]  2.6-  57.4,  p  =
0.002), PFo- canal- lengths (HR 1.2, 95%cI 1.1- 1.3,
p =  0.004) and extend of atrial-septal-aneurysm (HR
1.1, 95%cI 0.9- 1.3; p = 0.05). 4 (3.2%) arterial embol-
ic events occurred during a Fu-period of 817.2 pa-
tient-years, actuarial annual thromboembolic-risk was
0.49%. all ischemic events were not related to residual
PFo-shunting or device-related thrombus- formation.
Conclusion: success rates of PFo- closure are mainly
dependent  on  occluder-type,  extend  of  concomitant
atrial-septum-aneurysm  and  PFo-canal-  length.  Im-
portantly, residual shunting after PFo-closure was not
associated with recurrence of arterial embolism during
long-term follow-up.
oBJEctIvE
Patent foramen ovale (PFo) is an important cause of
paradoxical embolism. PFo presence alone increases
the  risk  of  recurrent  events  5-fold,  with  an  even 
higher  risk  in  case  of  concomitant  atrial  septal
aneurysm [1-3]. transcatheter PFo closure to prevent
recurrent  events  bears  a  low  risk  and  is  technically
feasible  with  high  success  rates  [2,  4-11].  anzola 
et al. showed that there are 9% of patients left with
residual  shunt  at  1  year  post  interventional  PFo 
closure  [12].  However,  there  is  still  the  question  of
clinical  outcome  for  different  catheter  devices  and 
the relevance of residual shunting on the recurrence
of ischemic events during long term follow-up (Fu)
[13]. 
the aims of this prospective cohort study were (i)
to evaluate the incidence of residual interatrial shunt-
ing after interventional PFo- closure, (ii) to identify
risk factors predicting residual interatrial shunting af-
ter successful device implantation and (iii) to investi-
gate the outcome of patients after PFo- closure dur-
ing a long- term Fu period of at minimum 5 years, fo-
cused on the recurrence of arterial embolism after de-
vice implantation.
MEtHods and MatERIal
In  a  prospective  observational  monocenter  cohort-
study,  symptomatic  patients  with  documented  PFo
undergoing interventional PFo-closure were enrolled
between May 2000 and april 2005 at the department
of cardiology, university of Bonn, germany.  Patients
with  other  identified  causes  for  systemic  embolism
were excluded from the study. PFo closure was per-
formed using four different devices according to de-
vice and size availability: 
1. amplatzer PFo occluder (aga Medical, Min-
neapolis, Minn., us; diameter 25 and 35 mm); 2. car-
dioseal occluder (nMt Medical, Boston, Mass., us;
diameter  23,  28  and  33  mm);  3.  Helex  occluder
(goREMedical Flagstaff, ariz., us; diameter: 15, 20,
25, 30 and 35 mm); 4. and Premere occluder (st. Jude
Medical,  st.  Paul,  Minn.  us;  diameter:  20  and 
25mm).
the study was approved by the local ethics commit-
tee, and all patients were asked to give their informed
consent.
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Follow-up  contrast  enhanced  transesophageal  echo  -
cardiography  (tEE)  after  valsalva  manoeuver  were
performed in all patients on days 1, 7 and 28, and on
months 3, 6, 12 and 24. at time of tEE, the patients
underwent clinical Fu examination for new onset of
arterial  embolism.  after  completion  of  echocardio-
graphic Fu-procedures, all patients were contacted 6
monthly by telephone call for the occurrence of clini-
cal endpoints, minimum Fu period was 5 years. 
EcHocaRdIogRaPHy
two-dimensional contrast enhanced echocardiography
was performed with commercially available ultrasound
scanner (vivid 7, gE Medical systems, wankesha, wI,
and iE33, Philips, andover, Massachusetts). a broad-
band transthoracic transducer and a multiplane trans-
esophageal  5-MHz  transducer  were  used.  For  ttE
and tEE a 20 gauge intravenous catheter was intro-
duced into the right antecubital vein. as right heart
contrast agent Echovist (Echovistﾮ, schering, Berlin,
germany) was administered with a bolus injection of
2–5 ml as needed for complete opacification of the
right heart chambers. the valsalva-maneuver was con-
ducted at each study visit and repeated until opacifa-
tion of the right atrium and interatrial septum after
valsalva manoeuvre was considered of sufficient quali-
ty [14, 15]. a PFo or residual shunt was determined
on contrast appearance of micro bubbles within three
cardiac cycles following opacification of the right atri-
um. the images were reviewed during the procedure
and  offline  by  a  single  experienced  observer.  atrial
septal aneurysm (asa) was defined as a membrane ex-
cursion of the interatrial septum of at least 10 mm
with a base diameter of the aneurysm of at least 15
mm.  under  tEE  spontaneous  or  induced  right-to-
left-shunt was defined as grade 0 if no bubbles could
be  detected.  grade  1  was  attributed  if  less  than  10
bubbles were seen.  grade 2 was defined if more or
equal  than  10  bubbles  up  to  a  distinct  contrast  jet
opacification was seen and grade 3 if a severe filling of
more than 25% of a left heart chamber was recorded.
grade 2 and 3 were regarded as significant shunts [5,
8].
dEvIcE IMPlantatIon
the PFo was crossed under fluoroscopic and tEE
guidance with a 4 or 6 F multipurpose catheter. de-
pending on the occluder-type either a 9 to 12 French
long sheath was placed across the atrial septum or a
short 12 French sheath with an over the wire tech-
nique was used. after thoroughly flushing the loaded
implantation system to prevent air embolism the de-
vice was placed under fluroscopic and tEE guidance
discharge from the hospital was on the next day after
post-interventional ttE/ tEE and 12 lead-Ecg ex-
amination. after implantation of PFo-occluder all pa-
tients received dual antiplatelet therapy with clopido-
grel  and  aspirin  for  3  months,  therafter  aspirin  was
given until 12 months after the procedure. In subjects
with  residual  interatrial  shunting  during  tEE,  an-
tiplatelet-therapy  with  aspirin  was  extended  until
echocardiography confirmed complete PFo- closure, 
clInIcal Follow-uP
clinical apparent arterial embolism was defined as is-
chemic  stroke,  transient  ischemic  attack,  myocardial
infarction, or systemic embolism. all patients with re-
current  arterial  embolism  underwent  additional  con-
trast-tEE for evaluation of the occluder system and
septal  anatomy.  all  documented  arterial  ischemic
events during the follow- up period were considered
to  be  PFo  related  unless  further  clinical  evaluation
confirmed other source of embolism. 
statIstIc
comparison  of  numerical  variables  was  performed
with the student t test or wilcoxon rank sum test, de-
pending on variable distribution. the chi-square test or
Fischer’s  exact  test  was  used  to  compare  qualitative
variables.  comparison  between  groups  was  analyzed
with one-way analysis of variance (anova) with Bon-
ferri’s post-tests. a cox multivariate analysis including
all variables with p value <0.2 in the cox univariate
analysis was used to determine the predictive factors of
cumulative late mortality.  survival rates up to 5 years
were presented as kaplan-Meier curves, and the log-
rank  test  was  used  for  comparison  between  groups.
differences were considered statistically significant at p
values <0.05. the data were analyzed with sPss statis-
tical software version 17 (sPss Inc., chicago, Il).
REsults
a consecutive series of 124 patients (31-76 years) with
a  history  of  ≥1  paradoxical  embolism,  of  that  70
(54.8%)  with  concomitant  atrial  septal  aneurysm
(asa) were treated with an amplatzer PFo occluder,
n = 52; cardioseal occluder, n = 33; Helex occluder,
n = 23; and Premere occluder, n = 16.
Mean-Fu-period was 6.7 ﾱ 1.3 years (range 5-9.75
years), overall 827.17 patient years were reviewed for
the occurrence of clinical endpoints. 
PRocEduRal dEtaIls
the 4 patients groups did not differ significantly with
respect to clinical variables such as age, sex and con-
comitant medication. In all patients, occluder devices
were successfully implanted. In 1 case, an amplatzer
PFo occluder that had embolized into the pulmonary
artery  24h  post  implantation  was  percutaneously
trapped, subsequently followed by the re-implantation
of a PFo occluder with bigger diameter during the
same procedure (baseline characteristics and procedur-
al details are listed in table 1).
REsIdual sHuntIng aFtER succEssFul
PFo-closuRE
closure rates increased from 65.3% immediately post-
procedure up to 82.3% after 6 months, 84.7% at 12
months  and  87.1%  at  24  months.  all  patients  were
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12, and 24 were 88.5, 88.5, 92.3, 94.2% with the am-
platzer-device; 81.8, 84.8, 87.9, 90.9% using the car-
dioseal device; 87.5, 87.5, 87.5, 87.5% after using the
Pemere occluder and 60.9, 60.9, 62.3, 65.2% for Helex
occluders, (Figures 1 and 2). 
the  observed  differences  in  time-to-closure-rates
were statistically significant (p- logrank  =  0.003, fig-
ure 2), this difference was predominantly driven by a
high rate of residual interatrial shunting after implan-
tation of a Helex-device, p-values for comparison be-
tween different occluder types after 24 months are giv-
en in table 2. 
RIsk FactoRs FoR REsIdual IntERatRIal sHunt
Results of univariate and multivariate analysis are giv-
en  in  tables  3a  and  3b.  Independent  predictors  for
residual interatrial shunt after technical successful per-
cutaneous  closure  of  PFo  were  implantation  of  a
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Table 1. Baseline characteristics and procedural details at time of PFo-closure.
Amplatzer CardioSeal Helex PREMERE
n  = 124 52 33 23 16
Demographic data
age 50.7 ﾱ12.9 47.3 ﾱ14.1 44.4 ﾱ11.1 55.6 ﾱ13.1
Male 28 53.8% 18 54.5% 7 30.4% 5 31.3%
Female 24 46.15% 15 45.45% 16 69.57% 11 68.75%
Follow-up [months] 87.8 ﾱ19.6 75.0 ﾱ9.6 79.4 ﾱ8.4 54.6 ﾱ3.0
cad 13 25.0% 5 15.2 3 13.0% 7 43.8%
Hyperlipidemia 27 51.9% 14 42.4% 12 52.2% 9 56.3%
Hypertension 26 50.0% 10 30.3% 8 34.8% 6 37.5%
smoking 15 28.8% 8 24.2% 2 8.7% 2 12.5%
diabetes mellitus 2 3.8% 1 3.0% 1 4.3% 2 12.5%
BMI (kg/m2) 27.2 ﾱ4.6 25.3 ﾱ3.9 24.4 ﾱ4.5 25.9 ﾱ3.9
Peripheral embolism 3 5.8% 2 6.1% 2 8.7% 0 0.00%
central embolism 4 7.7% 3 9.1% 2 8.7% 1 6.3%
tIa 17 32.7% 11 33.3% 13 56.5% 9 56.3%
stroke 36 69.2% 22 66.7% 9 39.1% 12 75.0%
Medication
aspirin 24 46.2 14 42.4 10 43.5 11 68.8%
vka 7 13.5 7 21.2 5 21.7 1 6.3%
clopidogrel 1 1.9 2 6.1 1 4.3 4 25.0%
acEI 8 15.4 5 15.2 1 2.0% 2 12.5%
statins 10 19.2 5 15.2 2 8.7 3 18.8%
diuretics 1 1.9 000 0% 1 6.3%
ccB 2 3.8 000 0% 2 12.5%
Echocardiographic data
Ejection fraction 56.4 ﾱ6.8 57.3 ﾱ5.0 57.1 ﾱ4.7 57.2 ﾱ7.3
left atrial diameter (mm) 39.6 ﾱ3.7 40.0 ﾱ4.4 39.45 ﾱ3.4 40.3 ﾱ4.9
asa 27 51.9% 17 51.2% 10 43.5% 14 85.7%
chiari network 1 1.9% 3 9.1% 2 8.7% 1 6.3%
Eustachian valve 14 26.9% 3 9.1% 3 13.0% 4 25.0%
Procedural data
Procedural success [%] 100 100 100 100
>1 placement attempt 6 11.5 2 6.1% 3 13.0% 0 0%
device size (mm) 22-35 17-33 20-35 20-25
Procedural complications
device embolization 1 1.9% 0 0% 0 0% 0 0%
air embolization 0 0% 1 3.03% 0 0% 0 0%
Pericardial effusion 1 1.9% 0 0% 0 0% 0 0%
Paroxysmal atrial fibrillation 1 1.9% 1 3.03% 0 0% 0 0%
BMI =  body mass index, tIa =  transitory ischemic attack, vka =  vitamin-k-antagonist, acEI =  angiotensin convertin en-
zyme inhibitor, ccB =  calcium canal blocker, cad = coronary artery disease, asa =  atrial septal aneurysm.
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dence interval [cI] 2.57- 57.43, p = 0.002), PFo-canal-
lengths [per mm] (HR 1.17, 95%cI 1.05- 1.31, p =
0.004) and extend of asa [per mm] (HR 1.13, 95%cI
0.95- 1.29; p = 0.05). the width of PFo and pre-pro-
cedural  determined  severity  of  inter-atrial  shunting
were  not  predictive  for  residual  shunting  after  24
months.
clInIcal outcoME data
during 6.67 ﾱ 1.31 years 4 arterial embolic events oc-
curred in 3 of 124 patients (2.4%). Reviewing 817.17
patient-years,  the  actuarial  annual  thromboembolic
risk was 0.49%. all ischemic events occurred in pa-
tients  without  incidence  of  residual  interatrial  shunt
during  contrast  enhanced  tEE.  one  patient  experi-
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Fig. 1. tEE results indicating device related closure rates during follow up. 
Fig.  2.  tEE  results  indicating  device  related
closure rates after 24 months.
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plaques,  another  patient  was  hospitalized  with  acute
peripheral leg ischemia due to embolization of an ab-
dominal aortic plaque and one patient experienced a
major-stroke after new onset of atrial-fibrillation with
echocardiographic proven thrombus formation within
the left atrial appendage.
Echocardiography  after  arterial  embolism  showed
correct  function  of  the  occluder  device.  statistical
analysis failed to identify risk factors predicting recur-
rent embolism.
In 1 case, a PFo was closed surgically due to a min-
imal  residual  shunt,  despite  this  patient  remained
asymptomatic after percutaneous PFo-closure.
dIscussIon
this is the first prospective study aiming to investigate
the incidence, predictors and clinical impact of persis-
tent interatrial shunting after successful interventional
closure of PFo during a long term follow up period.
Importantly, all patients underwent serial tEE exami-
nations for 24 months after the procedure and clinical
outcome data were acquired with a minimum Fu peri-
od was 5 years. 
the most important findings of this study are, that
(i) the prevalence of residual shunting after PFo-clo-
sure is relatively high with 13% after two years, (ii) in-
terventional success mainly depends on the choice of
closure- device and, (iii) the annual risk for recurrent
arterial embolism after technical successful PFo- clo-
sure is relatively low with 0.49% per patient-year, and
seems independent of persistent interatrial shunting. 
avaIlaBlE data
anzola et al. investigated 140 patients undergoing seri-
al  contrast-enhanced  transcranial  doppler  ofter
sucesseful percutaneous PFo-closure. during valsal-
va-strain a large shunt was detectable in 9% of pa-
tients after 12-months. only 1 ischemic event occured
in a patient with complete PFo closure [12]. the pa-
tients in this study did not undergo serial tEE- exami-
nations  after  PFo-  closure;  therefore,  device-related
thrombi could not be excluded as well as minor- resid-
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Table 2. comparison of different occluder types regarding the observed closure rates after 24 months.
Amplatzer CardioSeal Helex Premere
Amplatzer 1.0 <0.0001 1.00
CardioSeal 0.004 1.00
Helex 0.065
Premere
p
-
v
a
l
u
e
Table 3a. univariate analysis of single variables predicting residual interatrial shunting after interventional PFo- closure.
Factor HR 95% CI p
Premere 1,628 ,052 51,027 ,782
cardioseal 3,697 ,486 28,156 ,207
Helex 19,048 2,409 150,639 ,005
PFo length [mm] 1,162 ,998 1,353 ,054
asa[mm] 1,130 ,950 1,344 ,169
Eustachian valve 2,508 ,461 13,652 ,287
chiari network 3,758 ,510 27,722 ,194
severity of shunting 1,012 ,998 1,026 ,091
HR =  hazard ratio, cI =  confidence interval, asa =  atrial septum aneurysm, PFo =  persistent foramen ovale, Eustach =
prevalence of Eustachien valve, chiari =  prevalence of chiari-net
Table 3b. Multivariate-regression analysis for the most predictive factors for residual shunting after PFo-closure.
Factor HR 95% CI p
Helex 12.58 2.573 57.438 ,002
PFO-length 1,173 1.052 1,307 ,004
ASA 1,130 ,950 1,29 ,05
HR =  hazard ratio, cI =  confidence interval, PFo =  persistent foramen ovale, asa =  atrial septum anurysm.
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Fu was limited to 12 moths. 
More recently von Bardeleben et al. examined 357
patients undergoing PFo closure [16], after a mean
follow up period of 3.8 years the re-event rate of is-
chemic thromboembolism was 0.7% per patient year.
no relation to residual PFo-shunting or to thrombus
formation was seen, which is in concordance with our
results. However, Fu- period in our study population
was  significantly  longer  and  we  can  confirm,  that 
the event- rate remains low after more than 5 years of
Fu.
In contrast to our data windecker s et al. investigat-
ed in 1994 80 patients after percutaneous PFo closure
focussing on the long-term risk of recurrent throm-
boembolic  events  [17].  Interestingly,  in  this  cohort
study  the  actuarial  annual  risk  for  recurrent  throm-
boembolic events was 3.4% and the extent of post-
procedural shunt was the most important predictor for
recurrent paradoxical embolism. these early data must
be  interpreted  with  caution,  since  occluder-devices
and implantation-techniques may have improved over
the following years.
clInIcal IMPact oF REsIdual sHunt aFtER
tEcHnIcal succEssFul PFo closuRE
closure of PFo is technical feasible with high acute
success rates. the number of patients is consistently
increasing despite debate is still going on if this inter-
vention  really  helps  to  diminish  recurrent  ischemic
events since data from prospective randomized stud-
ies are lacking [5, 18-22]. Residual interatrial shunting
after PFo-closure is a frequent finding [12] and the
impact  on  the  patientsﾴ  clinical  outcome  is  unclear
and not systematically investigated. In this context our
data are very important, as we show, that the occur-
rence of arterial embolism after PFo closure is not
related to residual interatrial shunt. as a consequence,
routine  tEE  follow  up  after  technical  successful
PFo-closure seems not necessary in asymptomatic in-
dividuals. 
lIMItatIons
this study is limited by the single site data collection
and the non- randomized fashion. we cannot exclude
decision  bias  from  the  referring  physicians.  In  our
study  Fu  after  24  months  was  performed  by  tele-
phone call which helped to minimize the drop- out-
rate. the predictable value of the identified prognostic
variables must be tested prospectively before a validat-
ed risk score can be established.
conclusIon
although residual shunts may be documented soon af-
ter  device  implantation,  they  consistently  decrease
over  time  and  residual  shunt  is  detectable  in  about
13% of patients after two years of follow up. tran-
sient residual shunting was found more frequent with
PFo closure using the Helex (in up to 30- 40%) than
the amplatzer, Premere or cardioseal occluder. Pre-
dictors for residual shunts are PFo- anatomy and the
choice  of  closure  device.  clinically,  these  residual
shunts  were  not  accompanied  by  recurrent  throm-
boembolic events after a long term follow up period
of  at  minimum  5  years,  and  the  observed  embolic
event rate is low.
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